tbuckley/cabot-search huggingface dataset:
GC-TOF based metabolic profiling of human colon carcinoma
Authors: Carsten Denkert, Jan Budczies, Wilko Weichert, Tobias Kind, Silvia Niesporek, Aurelia Noske, Anna Buckendahl, Manfred Dietel, Oliver Fiehn
Journal: Cancer Research (2007)

2240   Metabolites are the end products of cellular regulatory processes, and their levels can be regarded as the ultimate response of biological systems to genetic or environmental changes. We have used a metabolite profiling approach to test the hypothesis that quantitative signatures of primary metabolites can be used to characterize molecular changes in human colon cancer in comparison with normal colon mucosa.  27 colon carcinomas and 18 samples from normal colon mucosa were analyzed by gas chromatography-time of flight mass spectrometry with automated mass spectral deconvolution. A total of 206 metabolites were detected. Carcinoma samples were compared to normal tissue samples using Welch’s t-test to assess the deregulation of each measured metabolite. At Bonferroni threshold (p  Predictive models (NMC, LDA, SVM) were fitted by a combination of feature selection and machine learning. Full Leave-one-out cross-validation gave 0-3 misclassifications out of 45 samples, e.g. prediction accuracies between 93% and 100%.  Our study shows that large scale metabolic profiling using GC-TOF mass spectrometry is suitable for analysis of human tumor tissue and that there is a consistent and significant change in primary metabolism of malignant colorectal tumors compared to normal tissue which can be detected using multivariate statistical approaches. Therefore metabolomics is a promising high-throughput, automated approach in addition to functional genomics and proteomics for analyses of molecular changes in malignant tumors.
4Ts HIT Scoring in the Medical-Surgical ICU
Authors: Mark A. Crowther, Diane Heels-Ansdell, David Williamson, John Granton, Lisa Burry, Francois Lamontagne, Simon Finfer, Ellen McDonald, Shirley Vallance, James Klinger, Jan Friedrich, Bojan Paunovic, Stephen Walter, Nicole Zytaruk, Deborah J Cook, Theodore E. Warkentin
Journal: Blood (2011)
Pilot Study of Thrice-Weekly Low-Dose Rituximab (RTX) in Chronic Lymphocytic Leukemia (CLL): Decreased CD20 Loss Via “Shaving” and a Novel Strategy for Enhanced Therapeutic Targeting.
Authors: Michael E. Williams, John J. Densmore, Andrew W. Pawluczkowycz, Paul V. Beum, Adam D. Kennedy, Margaret A. Lindorfer, Susan H. Hamil, Gina R. Petroni, Jane C. Eggleton, Ronald P. Taylor
Journal: Blood (2005)
PTH-135 A Dedicated PEG Service Can Improve Mortality and Clinical Outcome
Authors: A Shirazi-Nejad, A Chappell, N Rezwan, GSZ Tun, K Kapur, A Soliman, R Atkinson, V Sathyanarayana, D Bullas, E Said
Journal: Gut (2016)

<h3>Introduction</h3> The BSG guidelines<sup>1</sup> recommend that every endoscopy unit in an acute hospital setting should provide a basic percutaneous endoscopic gastrostomy (PEG) service, which is a part of the nutritional support team. The service should provide a framework for patient selection, pre-assessment and post-procedural care as well as working closely with the community-based services. Our trust recently appointed an accredited therapeutic endoscopist and gastroenterology nurse practitioner to run this service. <h3>Methods</h3> Retrospective analysis of all PEG insertions performed from Jan 2014 to Nov 2015 over a 23 month period. We looked at early-term (four weeks) and late term (eight weeks) mortality after PEG insertion. <h3>Results</h3> All patients were referred via a revised pathway proforma and examined by the team before the procedure to assess suitability. Further help and advice is offered to the community team upon discharge. 71 patients were referred for PEG insertion during the period of study. 29 (41%) were male, with a mean age 68 (range 29–87 years), 42 (59%) were female, with a mean age 69 (range 18–93 years). Indications for referrals included: 37 (52%) stroke related dysphagia, 15 (21%) head and neck cancers, 6 (8.5%) Huntington's disease, 4 (5.6%) traumatic head injury, 3 (4.2%) learning disability, 2 (2.8%) cerebral palsy, 2 (2.8%) multiple sclerosis, 1 (1.4%) supranuclear palsy, 1 (1.4%) mitochondrial myopathy, 1 (1.4%) syringomyelia, 1 (1.4%) parkinsonism, 1 (1.4%) Korsakoff's psychosis, and 1 (1.4%) myoclonic epilepsy with ragged-red fibres (MERRF) syrdrome. Patients with a formal diagnosis of dementia were not selected to undergo PEG insertion during this period. No short-term complications were reported post-insertion. Early-term mortality was 12.7% and late-term rose to 22.5%. Previous departmental audit in 2014 revealed early-term mortality of 20% and late-term mortality of 28%. <h3>Conclusion</h3> Meta-analysis has reported a 19% 30 day mortality following PEG insertion<b>.</b><sup>3</sup> We have shown that in our centre, both early and late-term mortality has improved due to careful patient selection and a dedicated PEG service. Adherence to the BSG guidelines on PEG service has had a direct impact on improving mortality and clinical outcome. <h3>References</h3> 1 Westaby D, Young A, O'Toole P, Smith G, Sanders DS. The provision of a percutaneously placed enteral tube feeding service. <i>Gut</i>. 2010;<b>59</b>:1592–1605. doi:10.1136/gut.2009.204982 2 Johnston S, Tham T, Mason M. Death after PEG: results of the national confidential enquiry into patient outcome and death. <i>Gastrointestinal Endoscopy</i> 2008;<b>68</b>:223–7. 3 Mitchell SL, Tetroe JM. Survival after percutaneous endoscopic gastrostomy placement in older persons. <i>J Gerontol A Biol Sci Med Sci</i> 2000;<b>55</b>:M735–9. <h3>Disclosure of Interest</h3> None Declared
PARE0003 What Do I Want To Talk about?
Authors: T. Bellerby, D. Stevens, L. Williamson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Face to face appointment time between patient and clinician is precious. Patients can wait months between appointments, and usually allow clinicians to take the lead in their consultations. These may concentrate on disease related outcome measures and treatment targets. Patients may not feel able to raise other issues, or may forget to ask about them. Waiting time for appointments is almost inevitable, so to help patients make best use of their waiting time we decided to add a "What Do I Want to Talk About" area. <h3>Objectives</h3> To assess patient response to "What do I Want to Talk About". <h3>Methods</h3> In the centre of patient waiting area we put up an "What Do I Want To Talk About" A4 poster, encouraging patients to write down the questions important for them to discuss within their consultation. We provided A6 paper sheets and pens for patients to take into their consultations. We asked patients to provide feedback by anonymous questionnaire asking these questions: Do you think this is a good idea? Yes/No; Have you used it? Yes/No. Would you use it in future? Yes/No; Other comments? <h3>Results</h3> 26 patients completed the questionnaire. Of these, 25 patients (96%) thought it was a good idea. 3 (12%) said they had used these slips previously. 18 (69%) said they would use them on their next visit. Comments: 9Good Idea thanks. I usually forget what I want to ask when I get in there and then remember on my way home9; "Why hasn9t this been done before?"; "I always do notes before my appointments as it helps both doctor and patient"; "This is a really good idea, and thanks for the pen" Clinician9s comments: "Really helpful for consultations, patients seem better prepared "; "I used the same paper to respond to questions and as an aide-memoire for patients" <h3>Conclusions</h3> 9What do I Want to Talk About9 is a very simple, universally applicable idea which uses minimal resources. It may help some patients better prepare for consultations, and ensure key issues important to patients are addressed during consultations. <h3>Disclosure of Interest</h3> None declared
WT1-Specific T Cell Responses Are Frequent after Allogeneic Stem Cell Transplantation for Acute and Chronic Myeloid Leukemia.
Authors: Chiara Gentilini, Urte Hilbers, Susanne Ganepola, Carmen Scheibenbogen, Katy Freyberg, Dietger W. Niederwieser, Eckhard Thiel, Lutz Uharek
Journal: Blood (2005)
FRI0155 Fifty Percent of Patients Who Tapered TNF-Blockers while in Stable Remission Are Able To Maintain A Tapered Regimen at 3 Year: Long Term Follow-Up Extension of The Strass Trial
Authors: J. Sigaux, F. Bailly, L. Gossec, T. Alfaiate, F. Gandjbakhch, V. Foltz, J. Morel, E. Dernis, P. Gaudin, O. Brocq, J.-M. Berthelot, J.-C. Balblanc, X. Mariette, F. Tubach, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Step-down strategy of spacing anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA) in remission are feasible in the context of randomized clinical trials (RCTs). However, we lack information on the long-term sustainability of a DAS driven step down strategy in clinical practice. <h3>Objectives</h3> This long-term extension study of a tapering RCT (STRASS trial (1)) aimed to assess the rate of patients who maintained the tapered regimen of etanercept (ETA) or adalimumab (ADA) in the in S-arm (progressive injection spacing) and M-arm (full regimen) and to evaluate the rate of treatment switch for inefficacy during the 3 years following the trial. <h3>Methods</h3> This observational 36 months follow-up considered all patients who completed the STRASS RCT (1). During the follow-up, the physicians were completely free of therapeutic decision making. Physicians were contacted between April and October 2015 and the data on the 36-month period after the end of trial retrospectively collected. The co-primary outcomes were the rate of patients who were taking their initial biologic at tapered regimen and the switch rate for loss of efficacy or safety. Percentage of full regimen anti-TNF intake was calculated over the 3 first years after trial end in both arms, using data from 12-monthly follow-up time points. <h3>Results</h3> 96 patients (70.1% of patients completing the RCT) had follow-up data available up to 3 years. At the end of the STRASS RCT (Table), 72 (75%) were in LDA or remission: 47 (48.9%) were taking ETA, 35 (36.5%), ADA, 2 (2.1%) another biologic and 12 (12.5%) no biologic because of remission. In addition, amongst patients still on their initial TNF blockers, 59/80 (74%) were treated at full regimen, 21/80 (26%) at tapered regimen. 3 years later, 65/96 (67.7%) were still on their initial anti-TNF: 73.1% vs 61.4% respectively in M and S-arm, p=0.23), either at full regimen 36/96 (38%), tapered regimen 29/96 (30%, 32% vs 29%, p=0.75), or completely stopped (11.5%: 5.8% vs 18.2%, p=0.06). 28 patients (29.2%, 25% vs 34.1%, p=0.33) had switched for another biologic. The mean percentage of full regimen of antiTNF over 3 years was 70.1±30.4%: respectively 74.3±28.2% vs 64.6±32.9% (p=0.19). DAS28-VS was not different between M and S-arm (2.42 vs 2.01 (p=0.23)). <h3>Conclusions</h3> Maintenance of anti-TNF was high (68% at 3 years) in this cohort of patients with established RA treated according to the treat-to-target paradigm, with no difference between the 2 initial RCT arms. More than 1/3 of patients were received tapered anti-TNF regimen. <h3>References</h3> Fautrel B, ARD 2016;75(1):59–67 <h3>Disclosure of Interest</h3> None declared
Effectiveness of Antibacterial Prophylaxis with Non-Absorbable Polymyxin B Compared to Levofloxacin after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Shiro Koh, Hirohisa Nakamae, Koichi Yamada, Mitsutaka Nishimoto, Yoshiki Hayashi, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Asao Hirose, Mika Nakamae, Hiroshi Kakeya, Masayuki Hino
Journal: Blood (2014)
Failure to engage clinicians is putting STPs at risk, says think tank
Authors: Gareth Iacobucci
Journal: BMJ (2016)

A failure to engage clinicians and the public is hindering the development of potentially controversial plans to reconfigure NHS services across England, a new analysis by the health think tank the King’s Fund has concluded.1

Proposals known as sustainability and transformation plans (STPs) have been drawn up in haste by representatives of the NHS and local authorities in 44 geographical areas of England, after NHS England set them a deadline of 21 October 2016 to submit blueprints for improving services and saving money over the next five years.

But the draft plans, which in some cases include cutting numbers of hospital beds and closing or downgrading local emergency departments, have provoked criticism from MPs, local authorities, and patients’ groups, which are concerned at the lack of transparency in the process.2

The King’s Fund, which …
Targeting MEK/MAPK Signal Transduction Module Potentiates Arsenic Trioxide (ATO)-Induced Apoptosis in Multiple Myeloma Cells through Multiple Signaling Pathways.
Authors: Paolo Lunghi, Nicola Giuliani, Laura Mazzera, Francesca Morandi, Luigi Salvatore, Marcellina Mangoni, Vittorio Rizzoli, Antonio Bonati
Journal: Blood (2007)
AB0843 Tramadol's Respiratory Effects in Subjects with Chronic Non-Specific Low Back Pain: A Randomised Controlled Trial
Authors: A.M. Ionescu, R. Popa, B.N. Manolescu, S. Tache, M. Berteanu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Chronic non-specific low back pain (CNSLBP) is defined as back pain localised at inferior portion of the rachis, without radiating anywhere else, lasting for more than 12 weeks, and whose etiology cannot be assigned to a specific injury, nerve compression, infection, tumor. This is the case in about 90% of all low back pain subjects. Nowadays physicians are aware that altered breathing patterns may be present in a proportion of individuals with CNSLBP. Researchers suggest that breathing patterns should also be evaluated in the presence of low back pain. Guidelines recommend therapeutic physical exercise as a first line treatment option in CNSLBP. That may be because pain itself contributes to loss of functioning, limits the subject9s participation to activities of daily living and produces disability among these subjects. As medication, WHO guideline suggests the use of weak opioids. Tramadol is a centrally acting analgesic, which produces its effect by binding to the μ-opioid receptors, and by inhibiting the release of noradrenaline and serotonine. Studies suggest that, despite its part-opioid mechanism of action, tramadol doesn9t produce respiratory depression as opioids do. <h3>Objectives</h3> Our study goal was to assess tramadol effects on respiratory markers in human subjects with CNSLBP. <h3>Methods</h3> A number of 30 subjects with CNSLBP joined this study for a period of 7 days. They were randomised in two groups: control (15 subjects, received placebo capsules twice a day), tramadol (15 subject, received tramadol 50 mg capsules twice a day). All subjects underwent cardio-pulmonary exercise testing using cycle-ergometer with progressive increasing work-rate at baseline and after 7 days of medication. We investigated peak oxygen uptake (VO<sub>2</sub>max), respiratory reserve (RR), and exercise tolerance expressed as dioxide carbon ventilatory equivalent. All these parameters were investigated in the first and 7th day of study. <h3>Results</h3> Peak oxygen uptake significantly raised for tramadol group on last day of the study (p=0.001). RR improved for both groups but the statistical difference came up for tramadol group (p=0.005). Exercise tolerance was better for both groups but it was significantly higher for tramadol group (p=0.98x10<sup>–5</sup>). <h3>Conclusions</h3> Tramadol administration to subjects with CNSLBP improved respiratory markers and exercise tolerance. <h3>References</h3> www.who.gov Rousse N, Nijs J, Truijen S, Vervecken L, Mottraw S, Stassijns G. Altered breathing patterns during lumbo-pelvic motor control tests in chronic low back pain: a case-control study. Eur Spine J. 2009; 18(7): 1066–1073. Hodges PW. The role of the motor system in spinal pain: implications for rehabilitation of the athlete following lower back pain. J Sci Med Sport. 2000; 3(3):243–253. <h3>Disclosure of Interest</h3> None declared
Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).
Authors: George Somlo, Ricardo Spielberger, Paul Frankel, Chatchada Karanes, Amrita Krishnan, Pablo Miguel Parker, Leslie Popplewell, Firoozeh Sahebi, Tim Schultheiss, Neil Martin Kogut, An Liu, David S. Snyder, Stephen J. Forman, Jeffrey Y. Wong
Journal: Blood (2008)
Acute Myeloid Leukemia (AML) Cells Alter the Bone Marrow Microenvironment By Inducing Osteogenic and Suppressing Adipogenic Differentiation of MSCs through BMP-RUNX2-CTGF Mediated Mechanisms
Authors: Venkata Lokesh Battula, Phuong M Le, Jeffrey Sun, Hong Mu, Teresa Mc.Queen, Elizabeth J Shpall, Marina Konopleva, Carlos E. Bueso-Ramos, Melvyn Harrington, Catherine W Palisch, Michael Andreeff
Journal: Blood (2015)
Ailing NHS finances are not sustainable, government auditors warn
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Government auditors have joined the growing chorus of organisations warning of the precarious state of finances of the NHS in England ahead of the chancellor’s autumn statement this week.

In a new analysis published on Tuesday 22 November, the National Audit Office (NAO) said that the financial performance of NHS bodies worsened considerably in 2015-16 and warned that the current situation was endemic and unsustainable.1

Trusts’ deficits grew by 185% to £2.45bn (€2.9bn; $3bn), up from £859m in 2014-15, and 32 clinical commissioning groups reporting cumulative deficits in 2015-16, up from 19 in …
SP0190 Lived Experiences of Intimate Life in Men and Women with Early RA
Authors: A. Sverker
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Women and men with rheumatoid arthritis (RA) experience restrictions in everyday life in spite of the development of new medications. Recent research has described in detail how participation limitations are experienced in everyday life from a patient perspective. However, knowledge of how sex and intimate relationships are affected is still scarce. <h3>Objectives</h3> The aim of this study was to explore sex life experiences in relation to sexual function and sexual relationships in women and men with early RA. <h3>Methods</h3> This study is part of the Swedish TIRA-project (the Swedish acronym for the prospective multi centre early arthritis project). The data collection includes 45 interviews with 24 women and 21 men, aged 20–63, which were recorded and transcribed verbatim. Critical Incident Technique was used to collect data, and content analysis to categorize the results. <h3>Results</h3> Half the participants stated that RA affected their sex life. The general descriptions formed five categories: sex life and tiredness, sex life and aging, emotional consequences of impaired sexual function, facilitators of sexual function and sexual relationships, and strain on the sexual relationship. <h3>Conclusions</h3> Sex life is still affected in early RA despite new effective treatment strategies. New strategies of communication, assessment and self-managing interventions concerning the sex life of patients with RA need to be implemented multi-professionally in health car <h3>Disclosure of Interest</h3> None declared
The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML.
Authors: ZiYi Lim, Laurence Pearce, Aloysius Y.L. Ho, Linda Barber, Wendy Ingram, Monica Usai, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti
Journal: Blood (2006)
Apoptosis Inducing Factor Acts as a Survival Factor in Acute Myelogenous Leukemia through Mitochondrial Complex 1.
Authors: Rui-yu Wang, Ismael J. Samudio, Teresa McQueen, Wendy D. Schober, Vivian R. Ruvolo, Steven Kornblau, Marina Konopleva, Michael Andreeff
Journal: Blood (2007)
P1170 : The role of growth hormone receptor in liver fibrosis and cancer
Authors: P. Stiedl, R. McMahon, L. Blaas, V. Stanek, J. Svinka, B. Grabner, G. Zollner, S. Kressler, T. Claudel, M. Müller, W. Mikulits, H. Esterbauer, R. Eferl, J. Haybaeck, M. Trauner, E. Casanova
Journal: Journal of Hepatology (2015)
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Authors: William R. Hiatt, F. Gerry R. Fowkes, Gretchen Heizer, Jeffrey S. Berger, Iris Baumgartner, Peter Held, Brian G. Katona, Kenneth W. Mahaffey, Lars Norgren, W. Schuyler Jones, Juuso Blomster, Marcus Millegård, Craig Reist, Manesh R. Patel
Journal: New England Journal of Medicine (2016)

Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.
Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas
Authors: Rodrigo A. Toledo, Nelly Burnichon, Alberto Cascon, Diana E. Benn, Jean-Pierre Bayley, Jenny Welander, Carli M. Tops, Helen Firth, Trish Dwight, Tonino Ercolino, Massimo Mannelli, Giuseppe Opocher, Roderick Clifton-Bligh, Oliver Gimm, Eamonn R. Maher, Mercedes Robledo, Anne-Paule Gimenez-Roqueplo, Patricia L. M. Dahia
Journal: Nature Reviews Endocrinology (2016)

As a large number of genes have been implicated in the development of hereditary phaeochromocytomas and paragangliomas (PPGLs), next-generation sequencing (NGS) technology is ideally suited for carrying out genetic screening. This Consensus Statement proposes specific recommendations for the use of diagnostic NGS in hereditary PPGLs. Phaeochromocytomas and paragangliomas (PPGLs) are neural-crest-derived tumours of the sympathetic or parasympathetic nervous system that are often inherited and are genetically heterogeneous. Genetic testing is recommended for patients with these tumours and for family members of patients with hereditary forms of PPGLs. Due to the large number of susceptibility genes implicated in the diagnosis of inherited PPGLs, next-generation sequencing (NGS) technology is ideally suited for carrying out genetic screening of these individuals. This Consensus Statement, formulated by a study group comprised of experts in the field, proposes specific recommendations for the use of diagnostic NGS in hereditary PPGLs. In brief, the study group recommends target gene panels for screening of germ line DNA, technical adaptations to address different modes of disease transmission, orthogonal validation of NGS findings, standardized classification of variant pathogenicity and uniform reporting of the findings. The use of supplementary assays, to aid in the interpretation of the results, and sequencing of tumour DNA, for identification of somatic mutations, is encouraged. In addition, the study group launches an initiative to develop a gene-centric curated database of PPGL variants, with annual re-evaluation of variants of unknown significance by an expert group for purposes of reclassification and clinical guidance.
A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Authors: Pieter Van Vlierberghe, Jules P.P. Meijerink, Charles Lee, Adolfo A. Ferrando, A. Thomas Look, Elisabeth R. van Wering, H. Berna Beverloo, Jon C. Aster, Rob Pieters
Journal: Blood (2005)
A Novel CD49d Targeting Antisense, ATL1102, Effectively Mobilizes Acute Myeloid Leukemia Cells
Authors: Yann Duchartre, EunJi Gang, Hye Na Kim, Stephanie Nicole Shishido, Muller Fabbri, Anatoly Grishin, Chintan Parekh, Hisham Abdel-Azim, Deepa Bhojwani, Alan S. Wayne, George Tachas, Yong-Mi Kim
Journal: Blood (2015)